New approaches to treating infections in cystic fibrosis patients - ar 501 phase 2 trial update

Ar-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cf patients
ARDS Ratings Summary
ARDS Quant Ranking